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Regulatory T (T reg) cells are subsets of CD4+ 
T cells that play crucial roles in immunological 
tolerance, transplantation, and autoimmunity 
(1–3). Among diff  erent types of T reg cells, 
naturally arising CD4+CD25+ T reg cells are 
the best characterized and studied. These cells 
comprise  5–10% of CD4+ T cells in periph-
eral lymphoid organs and represent a unique 
T cell lineage that undergoes thymic selection 
and migrates to the periphery (4–8). Natural T 
reg cells are characterized by cell surface ex-
pression of CD25 (the IL-2 receptor α-chain), 
CD62L (L-selectin), cytotoxic T lymphocyte 
antigen 4, and glucocorticoid-induced TNF 
receptor (GITR). The role of T reg cells in 
control of autoimmune diseases was clearly 
demonstrated in the experimental models in 
which elimination of CD25+ T cells results in 
acceleration of disease progression including 
infl  ammatory bowel disease, experimental au-
toimmune encephalomyelitis, and autoimmune 
diabetes (9).
Multiple signaling pathways govern the de-
velopment, function, and homeostasis of natu-
ral T reg cells including the IL-2 (10–15) and 
CD28 signaling pathways (16–18). In addition, 
the forkhead transcription factor, Foxp3, has 
recently been shown to be an essential regula-
tor of CD4+CD25+ T reg cell development 
(19–21). Studies using Foxp3 knock-out mice 
(Foxp3−/−) have shown that ablation of Foxp3 
expression results in mice lacking CD4+CD25+ 
T reg cells and the development of the lethal 
lymphoproliferative autoimmune disease char-
acterized by the uncontrolled proliferation of 
activated T cells. This disease can be prevented 
by transfer of CD4+CD25+ T reg cells. More-
over, overexpression of Foxp3 in CD4+CD25− 
T cells converts these lymphocytes into 
CD4+CD25+ T cells with suppressive biolog-
ical function (21). These fi  ndings suggest an 
obligatory role of Foxp3 in the development of 
natural T reg cells.
Engagement via the TCR is required for 
CD4+CD25+ T cell development (22–26). 
TCR engagement activates tyrosine kinases 
that further phosphorylate many cellular pro-
teins, leading to activation of signaling events 
such as Ras–MAPK activation and calcium 
fl  ux. A key protein that couples the signaling 
events to TCR engagement is the linker for 
activation of T cells (LAT) (27). LAT is a trans-
membrane adaptor protein that binds Grb2, 
Gads, and PLC-γ1. It is essential during T cell 
activation and thymocyte development (28). In 
addition, LAT also plays an important role in 
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immune homeostasis. Mice with a knock-in mutation of 
LAT at the PLC-γ1 binding site (Y136) show a severe auto-
immune disease (29, 30). Although TCR-mediated phos-
phorylation of LAT and PLC-γ1 and Ca2+ mobilization in 
LATY136F T cells are markedly reduced, T cells in these 
mice are hyperactivated and produce large amounts of Th2 
cytokines, which promotes B cell maturation and isotype 
switching. Spleens of these mice are enlarged enormously 
and lymphocytes infi  ltrate into diff  erent organs. It is not clear 
what causes the severe autoimmune phenotype in these mice. 
Defects in TCR signaling in LATY136F T cells might aff  ect 
negative selection as demonstrated recently (31), leading to 
production of autoreactive T cells in these mice. In addition, 
the signaling defects might also aff  ect development or sur-
vival of CD4+CD25+ T reg cells that are capable of control-
ling the autoimmunity. In this study, we demonstrated that 
LATY136F mice lacked CD4+CD25+ T cells expressing 
Foxp3 in peripheral lymphoid organs. Moreover, transfer of 
normal CD4+CD25+ T reg cells in LATY136F mice pre-
vented the lymphoproliferative syndrome. Ectopic expres-
sion of Foxp3 in LATY136F T cells conferred suppressive 
function to abrogate lymphoproliferative disease when trans-
ferred into LATY136F mice. Our fi  ndings provide the evi-
dence that the proximal signaling pathways downstream of 
the TCR, specifi  cally the LAT–PLC-γ1 interaction, control 
T cell homeostasis by regulating Foxp3 expression and devel-
opment of T reg cells.
RESULTS
The absence of CD4+CD25+ T cells in LATY136F mice
The interaction of the TCR and self-peptides presented 
by MHC class II plays a critical role in development of 
CD4+CD25+ T reg cells in the thymus and function in the 
periphery (6, 32), suggesting that TCR-mediated signaling 
might also be important in the development of T reg cells. 
We asked whether the severe autoimmune phenotype of the 
LATY136F mice might be caused by a defect in development 
or function of T reg cells. We fi   rst examined whether 
CD4+CD25+ T reg cells were present in LATY136F mice. 
Cells from thymuses and spleens of LATY136F and WT mice 
were analyzed for expression of CD4, CD8, and CD25 by 
FACS. As previously reported (29, 30), LATY136F mice had 
a partial block in thymocyte development with accumula-
tion   of CD4−CD8− cells (Fig. 1 A). Splenomegaly and en-
larged lymph nodes became obvious when they were 4–6 
wk old. In the periphery, the CD4+ to CD8+ ratio was 
skewed   toward CD4+ cells. Although discreet populations 
of CD4+CD25+ and CD4+CD25− SP thymocytes could be 
observed in WT mice, most of CD4+ SP thymocytes in 
LATY136F mice expressed low levels of CD25 (Fig. 1 A). The 
Figure 1.  Disruption of the LAT–PLC-𝗄1 interaction leads to the 
absence of CD4+CD25+ regulatory T cells in the periphery. (A) FACS 
analysis of CD4, CD8, and CD25 expression on thymocytes and spleno-
cytes from 6-wk-old WT and LATY136F mice. (B) Quantitative real-time PCR 
analysis of Foxp3 expression in thymocytes and splenocytes. Total RNAs 
were prepared from 2 × 105 CD4+ SP thymocytes and CD4+ splenocytes 
sorted by FACS. The levels of Foxp3 RNA were normalized with β-actin 
RNA. The data are representative of three independent experiments. 
(C) Expression of Foxp3 on CD4+ thymocytes and splenocytes from 6-wk-old 
WT and LATY136F mice by intracellular staining with an anti-Foxp3 antibody.JEM VOL. 203, January 23, 2006  121
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aberrant expression of CD25 in LATY136F thymocytes is likely 
caused by the partial block of thymocyte development in the 
DN3 (double negative) stage (29, 30), in which thymocytes 
are CD25+CD44−. Interestingly, double positive thymocytes 
in LATY136F mice also expressed CD25 (not depicted). Thy-
mocyte development in LATY136F mice might proceed with-
out down-regulation of CD25 expression.
Because thymocytes from LATY136F mice expressed 
CD25, we next examined whether CD4+CD25+ T cells are 
present in the periphery. CD4+CD25+ T cells were clearly 
missing in the periphery of these mice (Fig. 1 A), although 
CD4+ T cells from LATY136F mice expressed high levels of 
GITR (not depicted). We further determined expression of 
Foxp3, an important transcription factor that is specifi  cally 
expressed in CD4+CD25+ T reg cells, in LATY136F T cells. 
CD4+ SP thymocytes and CD4+ splenocytes cells were 
sorted from both WT and LATY136F mice. Foxp3 expression 
was determined by RT-PCR. The level of Foxp3 was de-
creased dramatically in CD4+ SP LATY136F thymocytes com-
pared with that in CD4+ SP WT thymocytes. Decrease in 
the level of Foxp3 mRNA was also observed in CD4+ T cells 
from the spleen of LATY136F mice (not depicted). Further 
quantitation of Foxp3 mRNA by real-time PCR showed that 
Foxp3 mRNA level in CD4+ SP thymocytes from LATY136F 
mice was  10-fold less than in WT thymocytes, and Foxp3 
RNA level in CD4+ splenic T cells from LATY136F mice was 
 30-fold less (Fig. 1 B). To exclude the possibility that de-
creased Foxp3 expression in CD4+ T cells from the mutant 
mice refl  ected dilution of Foxp3+ cells because of the expan-
sion of CD4+ T cells, Foxp3 expression in thymocytes and 
splenocytes from WT and LATY136F mice was examined by 
intracellular staining with an anti-Foxp3 antibody followed 
by fl  ow cytometry. As shown in Fig. 1 C, only CD4+ SP 
thymocytes and CD4+ splenocytes derived from WT, not 
those from LATY136F mice, expressed Foxp3. Thus, LATY136F 
mice lack CD4+CD25+ T reg cells.
To exclude the possibility that the severe autoimmune 
conditions cause disappearance of T reg cells, we also exam-
ined development of T reg cells in younger mutant mice in 
which the autoimmune disease was not severe. As a result of 
a partial block in thymocyte development, very few CD4+ or 
CD8+ T cells were found in the peripheral lymphoid organs 
of 17-d-old mice (not depicted); however, they appeared in 
the spleens from 24-d-old mice (Fig. 2 A). Interestingly, a 
high percentage of CD4+ SP thymocytes expressed CD25 
(23.6%). There was also a higher percentage (1.23%; Fig. 
2 A) of CD4+CD25+ splenocytes compared with 6-wk-old 
mice (0.1%; Fig. 1 A). However, these CD4+ cells from the 
mutant mice did not express Foxp3 as indicated by intra-
cellular staining (Fig. 2A). We also performed a mixed bone 
marrow chimeras experiment. Lethally irradiated LAT−/− 
mice were transferred with mixed bone marrow cells from 
WT Thy1.1+ and LATY136F Thy1.2+ mice. 6 wk after trans-
fer, these mice showed no apparent signs of lymphoprolifer-
ative disease, whereas LAT−/− mice received bone marrow 
cells from LATY136F mice developed the autoimmune disease 
like LATY136F mice (not depicted). Because of the partial 
block in thymocyte development in LATY136F mice, fewer 
Thy1.2+ T cells than Thy1.1+ T cells were detected even 
though more bone marrow cells from LATY136F Thy1.2+ 
mice were transferred. As expected, WT Thy1.1+ bone mar-
row cells gave normal population of CD4+CD25+ T cells. A 
small population of Thy1.1+ T cells expressed Foxp3, and 
these Foxp3+ cells also expressed CD25 (Fig. 2 B). In con-
trast, very few Thy1.2+ cells in thymuses and spleens, if any, 
Figure 2.  CD25 and Foxp3 expression in LATY136F T cells in young 
mice and mice with mixed bone marrow chimeras. (A) FACS analysis 
of CD4, CD8, CD25, and Foxp3 in thymocytes and splenocytes from 
24-d-old WT and LATY136F mice. (B) Irradiated LAT−/− mice were reconstituted 
with mixed bone marrow cells from Thy1.2+ LATY136F mice (3.0 × 106 cells) 
and congenic B6 Thy1.1+ mice (1.5 × 106 cells) after T cell depletion. 6 wk 
after reconstitution, thymocytes and splenocytes from these mice were 
analyzed. Cells were stained with APC anti-CD4, Texas red anti-CD25, 
PE-Cy5 anti-CD8, PE anti-Thy1.2 PE, biotin anti-Thy1.1, and strepavidin 
PE-Cy7 and FITC anti-Foxp3. FACS plot shown is a representative of 
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expressed Foxp3. Interestingly, diff  erent from the 6-wk-old 
LATY136F mice with the autoimmune disease, a large percent-
age of Thy1.2+ CD4+ splenocytes expressed CD25. It is pos-
sible that CD25 expression is down-regulated with progression 
of the disease. Because these Thy1.2+LATY136F T cells did 
not express Foxp3, they likely represented activated T cells. 
Collectively, these results indicate that LATY136F mice, which 
express a LAT mutant that does not bind PLC-γ1, have a 
defect in Foxp3 expression and development of CD4+CD25+ 
T reg cells.
Adoptive transfer of CD4+CD25+ T reg cells
To investigate whether the absence of CD4+CD25+ T 
reg cells is indeed one of the underlying mechanisms re-
sponsible for the lymphoproliferative syndrome in LATY136F 
mice, we purifi  ed CD4+CD25+ or CD4+CD25− T cells 
from congenic Thy1.1+ mice by FACS sorting. 2–3 × 105 
CD4+CD25+ or CD4+CD25− Thy1.1+ T cells were trans-
ferred into 3-d-old Thy1.2+ LATY136F neonatal mice by i.p. 
injection. These mice were analyzed at 7 wk after injection. 
Untreated LATY136F mice clearly developed a pathological 
lymphoproliferative syndrome at 7 wk of age as shown before 
(29, 30) (Fig. 3 A). Compared with untreated LATY136Fmice, 
LATY136F mice that received Thy1.1+CD4+CD25+ T cells 
had a normal size spleen and lymph nodes. In contrast, 
LATY136F mice injected with CD4+CD25− T cells developed 
a lymphoproliferative syndrome similar to untreated LATY136F 
mice (Fig. 3 A).
We further examined donor cell engraftment and expan-
sion of adoptively transferred cells in LATY136F recipient mice. 
In normal mice, CD4+CD25+ T cells comprise  5–10% of 
the peripheral CD4+ T cells or  1–2% of total cells in lymph 
node and spleen. FACS analysis 7–9 wk after adoptive trans-
fer revealed that 1–2% of the total cells in the lymph node 
and spleen of LATY136F mice adoptively transferred with 
CD4+CD25+ T cells were of donor origin, whereas very few 
donor cells were detected in the thymus (not depicted). This 
level of engraftment corresponded to  4–9-fold expansion 
of the initial donor cell inoculum of 2 × 105 cells. A similar 
degree of donor CD4+CD25+ T cell expansion was observed 
after injection of CD4+CD25+ T cells into Foxp3sf neonates 
(21). Likewise, CD4+CD25− injected into LATY136F neo-
nates also underwent a considerable degree of expansion 
as the number of Thy1.1+CD4+CD25− T cells increased 
Figure 3.  Neonatal adoptive transfer of normal CD4+CD25+ 
  regulatory T cells prevents the lymphoproliferative syndrome in 
LATY136F mice. Neonatal Thy1.2+ LATY136F mice were adoptively 
  transferred with 2–3 × 105 CD4+CD25+ or CD4+CD25−Thy1.1+ 
T cells and   analyzed 7 wk later. (A) Photographs of spleens and lymph 
nodes from 7-wk-old WT, LATY136F, LATY136F received CD4+CD25+, and 
LATY136F received CD4+CD25− T cells. This picture is a representative 
of six experiments. The numbers of splenocytes in these mice were 
9.3 × 107, 34.9 × 107, 9.8 × 107, and 31.0 × 107, respectively. 
(B) FACS analysis of donor cell engraftment. splenocytes were 
stained with FITC anti-Thy1.1 or FITC anti-Thy1.2, PE anti-CD25, and 
APC anti-CD4. The percentage of cells in the gated region is shown 
in the dot plot. FACS plot shown is a representative of fi  ve 
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at least 20-fold (not depicted). In contrast, only very few 
  donor-derived CD4+CD25+ and CD4+CD25− cells were 
detectable when they were transferred into age-matched 
WT recipients, which had normal T cell compartment. This 
observation reconciles with the possibility proposed by 
  Fontenot et al. that donor CD4+CD25+ T cells can expand to 
fi  ll the available homeostatic niche despite a skewed T cell 
compartment in these mice (21). In addition, adoptive  transfer 
of WT CD4+CD25+ and CD4+CD25− T cells into 3-wk-
old LATY136F mice that have not fully developed lymphopro-
liferative disease also resulted in expansion of both populations 
of donor-derived T cells (not depicted). However, only the 
transfer of CD4+CD25+ T cells was able to partially suppress 
lymphoproliferative disorder in 3-wk-old LATY136F recipi-
ents (not depicted). Neonatal adoptive transfer might provide 
donor-derived CD4+CD25+ T cell population with suffi   -
cient time to proliferate and suppress LATY136F T cells to fully 
suppress lymphoproliferative disorder. FACS analysis showed 
that in both groups of treated LATY136F mice >99% of the 
engrafted donor cells were still CD4+ T lymphocytes as ex-
pected. At least 75% of the donor CD4+ T cells expressed 
high levels of CD25 in the LATY136F mice transferred with 
CD4+CD25+ T cells, whereas the absolute majority of the 
donor CD4+ T cells were still CD25− in mice that received 
CD4+CD25− T cells. Adoptive transfer of either population 
of donor T cells had no eff  ect on expression of CD25 on the 
host T cells (Fig. 3 B).
No effect of donor T cells on the phenotypes of 
recipient T cells
To evaluate whether adoptive transfer of normal CD4+CD25+ 
T cells could change activated phenotypes or other intrinsic 
properties in the recipient T cells leading to suppression of 
the lymphoproliferative disorder, thymocytes and spleno-
cytes from LATY136F mice that received the adoptive transfer 
were analyzed and compared with those of untreated WT 
and LATY136F mice. Thymocyte development in LATY136F 
mice that received CD4+CD25+ T cells was similar to that 
in untreated LATY136F mice (Fig. 4 A). In fact, no substantial 
number of donor T cells was detected in the thymus of these 
mice (not depicted). However, the LATY136F mice trans-
ferred with CD4+CD25+ T cells had a signifi  cantly lower 
percentage of CD4+ T cells in the spleen ( 3%) compared 
with untreated WT (27%) and LATY136F (56%) mice. Despite 
a substantial reduction in the number of CD4+ T cells in 
LATY136F mice, donor CD4+CD25+ T cells did not alter the 
activated phenotypes of LATY136F T cells as T cells from both 
treated and untreated LATY136F mice were identical (CD25−
TCRβlowCD62LlowCD44high; Fig. 4 B). In addition, T cells 
from treated LATY136F mice failed to mobilize Ca2+-like 
T cells from untreated LATY136F mice (not depicted). These 
results indicate that donor CD4+CD25+ T cells did not 
change the activated phenotypes of LATY136F T cells based 
on these parameters we tested. Instead, CD4+CD25+ T reg 
cells transferred into LATY136F mice likely suppress expansion 
of CD4+ LATY136F T cells.
Rescue of the autoimmune phenotype in LATY136F mice
To determine if transfer of CD4+CD25+ T cells into 
LATY136F mice could correct the autoimmune disease, we 
performed a histological analysis of spleen, liver, and kidney 
from those mice. Histological sections from untreated 
LATY136F mice showed disorganized B and T cell zones in 
the spleen, lymphocyte infi  ltration in the majority of portal 
veins and liver sinusoids, and immune complex deposition in 
the glomeruli of the kidneys (Fig. 5 A). In contrast, tissue 
sections from LATY136F mice treated with CD4+CD25+ 
Figure 4.  Analysis of host-derived cells in LATY136F mice after 
adoptive transfer of CD4+CD25+ T cells. (A) FACS analysis of thymo-
cytes and splenocytes from untreated and treated LATY136F mice 7 wk after 
injection. (B) Expression of CD25, TCR-β, CD62L, and CD44 in host-derived 
Thy1.2+ CD4+ T cells from control and treated LATY136F mice. Numbers in 
the dot plots or histograms indicate the percentage of cells within the 
designated gate. The shaded area in the histogram represents FACS 
  staining of samples with isotype control antibodies. FACS plot shown is 
a representative of fi  ve independent experiments.124  LAT IN REGULATORY T CELLS | Koonpaew et al.
T cells appeared relatively normal, although many Thy1.2+ 
T cells did appear in the B cell zone of the spleen (Fig. 5 A). 
Histological analysis of the spleen, liver, and kidney of 
LATY136F mice that received CD4+CD25− T cells exhibited 
lymphoproliferative diseases similar to untreated LATY136F 
mice (not depicted).
Examination of serum antinuclear (not depicted) and 
anti–double stranded DNA antibodies revealed that LATY136F 
mice treated with CD4+CD25+ T reg cells had comparable 
levels to WT controls (Fig. 5 B). These data were in agree-
ment with a reduction in the number of   hyperactivated B 
cells (MHC class IIhi or IgM−B220+) in LATY136F mice 
treated with CD4+CD25+ T cells (Fig. 5 C). In addition, 
the concentration of IgG1 (Fig. 5 D) or IgE (not depicted), 
two antibody isotypes dramatically elevated in LATY136F 
mice as a result of increased B cell maturation (29), was 
  signifi  cantly reduced in mice treated with CD4+CD25+ 
T cells. Collectively, our data indicate that adoptive transfer 
of CD4+CD25+ T cells into LATY136F neonates can pro-
tect LATY136F mice from further developing lymphoprolif-
erative syndrome.
Up-regulation of granzymes in transferred CD4+CD25+ 
T cells
CD4+CD25+ T reg cells are capable of suppressing autoim-
mune disease; however, how these cells exert their sup  pressive 
function is still not clear. Inhibitory cytokines such as IL-10 
and TGF-β are considered to be the key   molecules involved 
in T reg cell–mediated immunosuppression (33). Recently, it 
was reported that CD4+CD25+ T cells up-regulate gran-
zyme B in vitro upon stimulation with anti-CD3 and IL-2 
(34). Whether this happens in vivo has not been demon-
strated. We asked whether CD4+CD25+ T reg cells up-
  regulate granzymes (A and B) or inhibitory cytokines when 
they are transferred into LATY136F mice. At 7 wk after adoptive 
transfer of CD4+CD25+ or CD4+CD25− Thy1.1+ T cells 
into LATY136F mice, donor cells were reisolated from these 
mice by FACS sorting. Because these Thy1.1+CD4+CD25+ 
T cells were placed in the autoimmune environment and 
  capable of correcting the disease, they must be activated to 
exert their suppressive function. They were labeled as “acti-
vated” in Fig. 5 E. We also isolated Thy1.2+CD4+CD25+ 
and CD4+CD25− T cells from WT mice as “resting” T reg 
Figure 5.  Effect of adoptive transfer of normal CD4+CD25+ 
T cells into LATY136F mice. (A) Immunohistochemistry staining of frozen 
sections of spleen (a–c), liver (d–f), and fl  uorescence staining of kidney 
(g–i). Frozen sections were prepared from the spleens, livers, and kidneys 
of 7- to 9-wk-old untreated controls and treated LATY136F mice. Spleen 
and liver sections were stained with anti-B220 (blue) and anti–TCR-β 
(red). Kidney sections were stained with anti–mouse IgG-FITC (green) for 
glomeruli. Spleen and kidney photographs were taken at ×10 magnifi  ca-
tion. Liver photographs were taken at ×100 magnifi  cation. (B) Anti–
  double-stranded DNA antibody titers in control untreated and LATY136F 
mice treated with CD4+CD25+ regulatory T cells. (C) Decrease in hyperac-
tivated B lymphocyte numbers (B220+MHCIIhi and B220+IgMlo) in treated 
LATY136F mice. (D) Reduced IgG1 production. IgG1 from serum samples of 
7-wk-old WT, LATY136F, and treated LATY136F mice were subjected to serial 
dilution and quantitated by ELISA. (E) Expression of Foxp3, granzyme A, 
granzyme B, and TGF-β. Thy1.2+ T cells (CD4+CD25+ and CD4+CD25−) 
were freshly isolated from normal C57BL/6 mice by FACS sorting. Thy1.1+ 
T cells were sorted from LATY136F mice received adoptive transfer of 
CD4+CD25+ or CD4+CD25− T cells from Thy1.1+ mice, respectively. 
Amounts of cDNAs used RT-PCR were normalized by the level of β-actin. 
Data in B and D represent mean ± SD of serum samples from fi  ve 
groups of mice.JEM VOL. 203, January 23, 2006  125
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cells and Thy1.2+CD4+CD25− T cells as a negative control. 
Total RNAs were prepared from these cells and used in 
RT-PCR.
Donor-derived Thy1.1+CD4+CD25+ T cells expressed 
a high level of Foxp3 similar to Thy1.2+CD4+CD25+ cells 
  directly isolated from WT mice. Thy1.1+ or Thy1.2+ 
CD4+CD25− T cells did not have a substantial level of Foxp3 
expression (Fig. 5 E). Interestingly, Thy1.1+CD4+CD25+ T 
cells from neonatally injected LATY136F mice expressed high 
levels of granzyme A, granzyme B, and TGF-β RNAs com-
pared with Thy1.2+CD4+CD25+ T cells (Fig. 5 E), whereas 
their IL-10 expression was comparable to that of resting T reg 
cells (not depicted). This result is consistent with recent fi  nd-
ings in which a granzyme B–dependent mechanism was iden-
tifi  ed as contact-mediated suppression by CD4+CD25+ T cells 
in vitro (34). Increased TGF-β expression could also function 
to suppress the expansion of CD4+ T cells from LATY136F 
mice. It is possible that transferred Thy1.1+CD4+CD25+ T 
cells use both cytokine-mediated and contact-mediated mech-
anisms to suppress hyperproliferative host CD4+ T cells in 
vivo. Although we have not demonstrated that increased gran-
zymes or TGF-β indeed mediates suppression in LATY136F 
mice, our results show that T reg cells indeed up-regulate these 
proteins in the autoimmune environment.
Ectopic expression of Foxp3 in LATY136F T cells
Ectopic expression of Foxp3 was previously shown to be 
  suffi     cient to activate a program of immunosuppression in 
CD4+CD25− T cells (21). Because Foxp3 expression was 
signifi  cantly decreased in LATY136F T cells (Fig. 1, B and C), 
we asked whether reexpression of Foxp3 in LATY136F 
T cells could confer the regulatory function that normal 
CD4+CD25+ T cells have. Because LATY136F T cells express 
low levels of TCRs on their surface, they were diffi   cult to be 
activated via the TCR. Instead, LATY136F T cells were stim-
ulated with PMA and ionomycin and cultured in the pres-
ence of IL-2 for 48 h before transduction with retroviruses 
  expressing Foxp3 and green fl   uorescence protein (GFP) 
(pHSpG-Foxp3) or GFP alone (pHSpG-Empty) (Fig. 6 A). 
After culture for an additional 48 h postretroviral transduc-
tion, GFP+CD4+ T cells were FACS sorted, and 2−3 × 105 
purifi  ed GFP+CD4+ LATY136F T cells were i.p. injected into 
3-d-old LATY136F neonates. Expression levels of TCR-β and 
the GITR on transduced LATY136F CD4+ T cells with or 
without Foxp3 were similar, whereas those of CD25 were 
slightly higher on pHSpG-Foxp3–transduced cells (Fig. 6 A). 
Expression of high levels of CD25 in these cells is likely a 
consequence of stimulation by PMA and ionomycin. 6 wk 
posttransfer, spleens and lymph nodes were harvested and 
examined. Mice receiving purifi  ed  LATY136F T cells ex-
pressing only GFP developed a severe lymphoproliferative 
  syndrome like untreated LATY136F mice (Fig. 6 B). In con-
trast, mice that received LATY136F T cells expressing Foxp3 
and GFP exhibited no sign of lymphoproliferative disease as 
judged by the gross appearance of secondary lymphoid or-
gans (Fig. 6 B). Analysis of GFP− T cells from mice received 
CD4+ LATY136F T cells expressing Foxp3 and GFP revealed 
a dramatic decrease in CD4+ T cells similar to that observed 
in LATY136F mice that received normal CD4+CD25+ T cells. 
On the other hand, GFP− host T cells from LATY136F mice 
treated with CD4+ LATY136F T cells expressing GFP alone 
were predominantly CD4+ similar to those in LATY136F mice 
(Fig. 6 C). These data indicate that reconstitution of Foxp3 
expression in LATY136F T cells is suffi   cient to induce suppres-
sive function and protect LATY136F mice from lymphoprolif-
erative disease.
DISCUSSION
In this study, we demonstrated an essential role of the adaptor 
protein LAT in Foxp3 expression and CD4+CD25+ T reg 
cell development. In LATY136F mice with a severe lympho-
proliferative disease, CD4+CD25+ cells were nearly absent 
in peripheral lymphoid organs. Foxp3 expression was also 
dramatically decreased in the LATY136F T cells. Interestingly, 
in young LATY136F mice CD4+CD25+ cells could be found; 
however, they did not express Foxp3. Similar results were 
also seen in LAT−/− mice that received mixed WT and 
LATY136F bone marrow chimeras. These data indicate that 
the LAT–PLC-γ1 interaction is required for Foxp3 expres-
sion and T reg cell development. Severe lymphoproliferative 
disease in LATY136F knock-in mice could be prevented 
by transfer of normal CD4+CD25+ T reg cells but not 
CD4+CD25− T cells. Our results indicate that the lympho-
proliferative disease associated with the LATY136F mutation is 
not only caused by abrogation of central tolerance (31), but 
also by a breakdown in peripheral tolerance caused by a se-
vere block of CD4+CD25+ T reg cell development.
Analysis of donor cell engraftment indicates that 
CD4+CD25+ and CD4+CD25− T cells are able to proli-
ferate and expand in LATY136F mice. Two studies using 
IL-2Rβ– and Foxp3-defi  cient mice have previously demon-
strated a similar expansion after the transfer of CD4+CD25+ 
T reg cells (12, 21). A rich Th2 cytokine environment, a con-
sequence of hyperactivated LATY136F CD4+ T cells, may 
  provide an ideal environment to support the expansion of 
transferred CD4+CD25+ and CD4+CD25− T cells. In 
LATY136F mice, at 2–3 wk after birth both CD4+ and CD8+ 
T cells begin to fi  ll in peripheral lymphoid organs as a result 
of a partial block in thymocyte development. Nonselective 
expansion of transferred T cells might be caused by the 
  lymphopenic environment in neonatal LATY136F mice. Adop-
tive transfer of CD4+CD25+ and CD4+CD25− T cells into 
3-wk-old LATY136F recipient mice also allowed engraftment 
and expansion of both T cell populations. Thus, it is also 
  possible that this expansion of transferred T reg cells may 
  result from a proliferative response to fi  ll a homeostatic niche 
for CD4+CD25+ T cells (10, 35). Although donor-derived 
CD4+CD25− T cells expanded upon transfer into LATY136F 
neonates, only transfer of CD4+CD25+ T cells into LATY136F 
mice rescued the lymphoproliferative disease. Even though 
CD4+CD25− T cells could convert into CD4+CD25+ 
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T cells injected into neonatal or 3-wk-old LATY136F mice 
neither converted into a considerable number of CD4+CD25+ 
T cells nor rescued the lymphoproliferative disease.
The appearance of CD4+CD25+ LATY136F T cells in pe-
ripheral lymphoid organs of mixed bone marrow chimeras or 
young mutant mice was unexpected because CD25 expres-
sion was almost absent on CD4+ T cells from LATY136F mice 
older than 6 wk. However, in mice that received treatment 
of CD4+CD25+ at the neonatal stage CD25 expression on 
LATY136F CD4+ T cells was still missing. Regardless of CD25 
expression in LATY136F T cells from diff  erent mice, Foxp3 
expression was not detected in these cells, suggesting that 
these cells are likely activated T cells, not real T reg cells. It is 
possible that IL-2 produced by WT T cells might induce or 
maintain a high expression level of CD25 on LATY136F T 
cells or the autoimmune environment in LATY136F mice may 
cause T cells to gradually lose CD25 expression. Neonatally 
injected T reg cells, which do not secret IL-2 (4, 22, 37), 
failed to restore CD25 expression on LATY136F T cells in 
these mice and provided only protective function against 
lymphoproliferative disease. Previous studies show that Foxp3 
is up-regulated upon activation of CD4+CD25+ T reg cells, 
and that ectopic Foxp3 expression confers suppressor func-
tion upon peripheral CD4+CD25− T cells (21). Likewise, 
ectopic expression of Foxp3 conferred LATY136F CD4+ T 
cells a regulatory function that prevents autoimmunity in 
these knock-in mice. Although ectopic expression of Foxp3 
had no eff  ect on the levels of both TCR-β and GITR, CD25 
was slightly up-regulated on transduced CD4+ T cells of 
LATY136F mice. It is diffi   cult to conclude the eff  ect of Foxp3 
on CD25 in our experiments because we had to activate 
LATY136F T cells with PMA and ionomycin, which up-
regulate CD25 in vitro, before transducing these cells with 
retroviruses. Nevertheless, our results suggest that Foxp3-
mediated suppression does not require normal function of 
LAT, perhaps independent of the TCR. Our data strongly 
support the notion that Foxp3 is a master regulator gene that 
controls suppressor function in CD4+CD25+ T cells.
Figure 6.  Expression of Foxp3 confers suppressive function in 
LATY136F CD4+CD25− T cells. (A) Retroviral constructs and retroviral 
transduction effi  ciency of CD4+LATY136F cells before neonatal injection. 
Retrovirally transduced cells were stained with fl  uorescent-conjugated 
APC anti-CD4 and PE anti–TCR-β, PE anti-GITR, and PE anti-CD25 
  antibodies, respectively. Gated GFP+CD4+ cells were analyzed for 
  expression of TCR-β, GITR, and CD25. (B) Representative spleens and 
lymph nodes of 6-wk-old untreated WT, LATY136F mice and treated 
LATY136F mice injected with either 2 × 105 T cells expressing GFP alone 
or GFP and Foxp3. The picture shown is a representative of four experi-
ments. (C) FACS analysis of CD4 and CD8 expression on splenocytes of 
recipient origin.JEM VOL. 203, January 23, 2006  127
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The LAT–PLC-γ1 interaction is important in TCR-
  mediated Ca2+ fl  ux and MAPK activation (38, 39). LATY136F 
T cells have abrogated Ca2+ fl  ux although TCR-mediated 
MAPK activation is normal (30). As the infl  ux of extracellu-
lar Ca2+ after TCR engagement has been implicated in in-
fl  uencing the outcome of both positive and negative selection 
(40–42), it is also possible that TCR-mediated Ca2+ mobili-
zation and further NFAT activation might be required for 
induction of Foxp3 expression. Interestingly, the phenotype 
of LATY136F mice resembles that of mice lacking NFATc2 
and NFATc3 (43), which suggests that the autoimmune 
  disease in these mice may be attributed, at least in part, to a 
decrease in NFAT activation. However, it has been demon-
strated that combined NFATc2/c3 defi  ciency has no eff  ect 
on development and function of CD4+CD25+ T cells but 
renders CD4+CD25− T cells unresponsive to suppression 
(44). Based on these fi  ndings, we speculate that the LAT–
PLC-γ1 interaction provides signals other than NFAT acti-
vation to induce Foxp3 expression. Because LATY136F CD4+ 
T cells can be suppressed in vivo, NFATc2/c3, which are 
required for CD4+CD25− T cells to be suppressed, might be 
activated independent of the TCR. Although our results 
  indicated that the LATY136F mutation aff  ected  Foxp3 
  expression and T reg cell development, we cannot rule out 
the possibility that the LATY136F T reg cells can develop, 
but they might not be able to survive in these mice. In addi-
tion, because T cell   development is partially blocked in the 
LATY136F mice, it is possible that the defect in Foxp3 ex-
pression and T reg cell development might be indirect con-
sequences of the block in thymocyte development. The 
signaling pathways that link the LAT–PLC-γ1 association 
and Foxp3 expression or T reg cell development remain to 
be explored in the future.
A dramatic decrease in peripheral CD4+ T cells in treated 
LATY136F mice strongly indicates that these autoreactive 
CD4+ T cells are the targets of CD4+CD25+ T cell– mediated 
suppression. Our data show that donor-derived CD4+CD25+ 
T cells from treated LATY136F mice expressed high levels 
of granzyme A, granzyme B, and TGF-β compared with 
CD4+CD25+ T cells isolated directly from WT mice (Fig. 
5 E). In normal mice, maintenance of central   tolerance mech-
anisms by negative selection leaves only a scanty number of 
these potentially harmful T cells in the periphery. The major-
ity of T reg cells may never encounter these self-reactive T 
cells and thus remain at the resting status. Once placed or 
  exposed to the autoimmune conditions, CD4+CD25+ T reg 
cells may trigger both contact-  dependent and cytokine-
  mediated mechanisms by secretion of granzymes and TGF-β. 
Whether these proteins indeed function to kill or suppress 
CD4+ LATY136F T cells in vivo remains to be determined in 
the future. In conclusion, our study indicates that the proxi-
mal signaling pathways downstream of the TCR mediated 
by the LAT–PLC-γ1 interaction play an important role 
in CD4+CD25+ T cell development and opens up the ques-
tion of what might be the missing link between TCR and 
Foxp3 induction.
MATERIALS AND METHODS
Mice. All mice were used in accordance with the National Institutes of 
Health guidelines. The experiments described in this study were reviewed 
and approved by the Duke University Institutional Animal Care and Use 
Committee. Mice were housed in specifi  c pathogen-free conditions at the 
Duke University Animal Care facility.
Antibodies. Streptavidin-conjugated Texas red and PE-Cy7 and biotinyl-
ated FITC, PE, and PE-Cy5, APC-conjugated antibodies to TCR-β, CD4, 
CD8α, CD25, B220, CD62L, CD44, GITR, Thy1.1, Thy1.2, IgM, IAb, 
and mouse Ig were purchased from BD Biosciences. The anti-Foxp3 anti-
body was from eBioscience.
Cell purifi  cation. Cells were maintained in complete RPMI 1640 medium 
with 10% FCS. To isolate CD4+CD25+ and CD4+CD25− T cells, spleno-
cytes and lymph node cells were isolated. CD8+ T and B cells were depleted 
by magnetic beads using biotin-conjugated anti-CD8 and anti-B220. The 
enriched CD4+ lymphocytes were stained with FITC–anti-CD4, PE–anti-
CD25, and 7AAD. CD4+CD25+ and CD4+CD25− T cells were purifi  ed 
by cell sorting using a FACSVantage SE fl  ow cytometer (BD Biosciences).
Neonatal transfer of CD4+ T cells. 2–3 × 105 WT Thy1.1+-marked 
CD4+CD25+ or CD4+CD25− T cells were injected i.p. into 3-d-old 
(Thy1.2+) LATY136F pups or 3-wk-old LATY136F mice. These LATY136F pups 
were derived from breeding LAT+/Y136F females with LAT−/− males. In-
jected pups were analyzed at 7−9 wk after the adoptive transfer. Donor cell 
recovery was calculated based on the total number of lymphocytes multi-
plied by the percentage of Thy1.1+ cells as determined by FACS analysis.
Mixed bone marrow transfer. T cell–depleted bone marrow cells from 
Thy1.2+ LATY136F mice (3.0 × 106 cells) were mixed with Thy1.1+ con-
genic mice (1.5 × 106 cells) and were then injected i.v. into irradiated LAT−/− 
mice (900 rads). 6 wk after bone marrow reconstitution, thymuses and 
spleens were harvested and analyzed by FACS.
Retroviral transduction of LATY136F CD4+CD25− T cells. pHSpG 
and pHSpG/Foxp3 retroviral vectors were used to transfect the Phoenix-
ecotropic virus packaging cell line using the calcium phosphate method 
to produce recombinant retroviruses. To transduce T cells from LATY136F 
mice, splenocytes from LATY136F mice were fi  rst activated using 40 ng ml−1 
PMA and 0.5 μg ml−1 ionomycin and recombinant mouse IL-2 (100 ng 
ml−1) for 36 h. Activated lymphocytes were then transduced by mixing with 
the retroviral supernatant in the presence of 8 μg ml−1 polybrene and re-
combinant mouse IL-2 (100 ng ml−1). Cells were then centrifuged at 1,300 
g for 2 h at 22°C. After culturing those cells at 37°C for 24 h, the transduc-
tion procedure was repeated. At 48 h after viral transduction, GFP+CD4+ T 
cells were sorted by FACS and 2−3 × 105 GFP+CD4+ T cells were injected 
i.p. into LATY136F neonates. At 6 wk after injection, lymph node and spleen 
cells were isolated and analyzed.
Real-time quantitative PCR and RT-PCR. Total RNAs were ex-
tracted with the Trizol reagent (Invitrogen) and reverse transcribed using 
Superscript II reverse transcriptase (Invitrogen). cDNAs were then used as 
templates in PCR amplifi  cation with Taq polymerase. The Foxp3 mRNA 
level was quantifi  ed using the LightCycler system (Roche). The primer pairs 
used in real-time PCR were the following: β-actin, 5′-A  C  T  C  C  T  A  T  G  T  G-
G  G  T  G  A  C  G  A  G  -3′, 5′-CAGGTC-C  A  G  A  C  G  C  A  G  G  A  T  G  G  C  -3′; Foxp3, 
5′-C  C  C  A  G  G  A  A  A  G  A  C  A  G  C  A  A  C  C  T  T  -3′, 5′-TTCTCA-C  A  A  C  C  A  G  G  C-
C  A  C  T  T  G  -3′. The primer pairs used in RT-PCR were the following: 
Foxp3, 5′-C  A  G  C  T  G  C  C  T  A  C  A  G  T  G  C  C  C  C  T  A  G  -3′, 5′-C  A  T  T  T  G  C  C-
A  G  C  A  G  T  G  G  G  T  A  G  -3′; granzyme A, 5′-C  T  C  A  A  G  A  C  C  G  T  A  T  A  T  G  G-
C  T  C  T  -3′, 5′-C  C  T  G  C  A  C  A  A  A  T  C  A  T  G  T  T  T  A  G  T  -3′; granzyme B, 
5′-A  C  T  T  T  C  G  A  T  C  A  A  G  G  A  T  C  A  G  C  A  -3′, 5′-A  C  T  G  T  C  A  G  C  T  C  A  A  C-
C  T  C  T  T  G  T  -3′; TGF-β1, 5′-T  G  C  T  G  C  T  T  T  C  T  C  C  C  T  C  A  A  C  C  T  -3′, 
5′-C  A  C  T  G  C  T  T  C  C  C  G  A  A  T  G  T  C  T  G  A  -3′.128  LAT IN REGULATORY T CELLS | Koonpaew et al.
Immunohistochemistry. Whole spleens, livers, and kidneys were embed-
ded in Tissue-Tek (Sankura Torrance) and sliced into 5-μm-thick section. 
Sections were applied to poly lysine–coated slides and fi  xed in acetone. 
Spleen and liver sections were then stained with FITC-conjugated anti-
B220 or biotin-conjugated anti-Thy1.2 followed by alkaline phosphatase-
conjugated anti-FITC and horseradish peroxidase–conjugated streptavidin 
(Sigma-Aldrich). Fast Blue BB and 3-aminoethylcarbazole (Sigma-Aldrich) 
solution were added for color development. Kidney sections were stained 
with FITC–anti–mouse IgG (BD Biosciences).
Autoantibody detection. Anti–double-stranded DNA antibodies were 
detected using ELISA. 96-well plates were coated with 2.5 μg ml−1 calf thy-
mus DNA in Reacti-bind DNA coating solution (Pierce Chemical Co.). 
Anti-nuclear antibodies were detected using slides of Hep-2 cells adhered to 
slides from Antibodies Inc.
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